28 Sep Genocea Biosciences
Chip Clark, President and CEO
Genocea harnesses the immune system to reveal the optimal targets for each patient to develop cancer immunotherapies that we hope will be better, more accessible and more affordable. Our proprietary ATLAS™ technology is a clinically validated platform that selects therapeutically relevant antigens that drive powerful anti-tumor immune responses. ATLAS is the only platform able to identify Inhibigens™ that can reverse or dampen the immune responses.